Results 281 to 290 of about 2,347,137 (336)

Nanoparticle‐Mediated Targeted Protein Degradation: An Emerging Therapeutics Technology

open access: yesAngewandte Chemie, EarlyView.
Targeted protein degradation (TPD) has emerged as a powerful therapeutic approach, with numerous candidates molecules now advancing into clinical development. Recent innovations have incorporated nanoparticles to facilitate and enhance these degradation processes, yielding synergistic effects.
Andrew G. Baker   +3 more
wiley   +1 more source

Mucosal immunotherapy targeting APC in lung disease. [PDF]

open access: yesJ Inflamm (Lond)
Liu Y   +4 more
europepmc   +1 more source

Catch, Cut, or Block? Versatile 4‐N‐Derivatized Sialyl Glycosides for Influenza Virus Neuraminidase Detection and Purification

open access: yesAngewandte Chemie, EarlyView.
Sialyl glycosides containing 4‐N‐derivatized sialic acids synthesized by a highly efficient one‐pot two‐enzyme (OP2E) chemoenzymatic sialylation strategy have been shown to be versatile probes. They can resist sialidase cleavage, be selective substrates by influenza sialidases, or be nanomolar substrate analog‐based inhibitors and affinity ligands ...
Yue Yuan   +6 more
wiley   +1 more source

Comparison of immunogenicity of 17 Burkholderia mallei antigens and whole cell lysate using indirect ELISA. [PDF]

open access: yesJ Vet Med Sci
Ichikawa Y   +12 more
europepmc   +1 more source

Influence of Alcohol on the Intestinal Immune System. [PDF]

open access: yesAlcohol Res
Kreimeyer H, Llorente C, Schnabl B.
europepmc   +1 more source
Some of the next articles are maybe not open access.

Related searches:

Antigen Capture and Immune Modulation by Bacterial Outer Membrane Vesicles as In Situ Vaccine for Cancer Immunotherapy Post-Photothermal Therapy.

Small, 2022
Tumor antigens released from tumor cells after local photothermal therapy (PTT) can activate the tumor-specific immune responses, which are critical for eliminating the residual lesions and distant metastases.
Yao Li   +12 more
semanticscholar   +1 more source

Home - About - Disclaimer - Privacy